Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.

Abstract:

:Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect their true biologic efficacy. Thus, it is crucial to identify biomarkers that permit the recognition of potentially responsive subjects and to spare toxicity in those who are unlikely to benefit from treatment. Circulating endothelial cells (CECs) have been recently indicated as potential surrogate biomarkers of angiogenesis in several types of cancer. The possibility of rapidly quantifying these cells represents a promising tool for monitoring the clinical outcome of tumors with the potential to assess response to various treatments. However, the identification and quantification of CECs is technically difficult and not well standardized. A variety of methods to detect CECs in patients with solid tumors have been used; these are based on different technical approaches, combinations of surface markers, sample handling, and staining protocols. With an expanding interest in the field of potential clinical applications for CECs in oncology, the development of standardized protocols for analysis is mandatory. The aim of this review was to critically summarize the available data concerning the clinical value of CECs and their subpopulations as biomarkers of antiangiogenic therapy in patients with metastatic colorectal cancer.

journal_name

Clin Colorectal Cancer

authors

Manzoni M,Comolli G,Torchio M,Mazzini G,Danova M

doi

10.1016/j.clcc.2014.12.002

subject

Has Abstract

pub_date

2015-03-01 00:00:00

pages

11-7

issue

1

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(14)00133-9

journal_volume

14

pub_type

杂志文章,评审
  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.08.002

    authors: Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

    更新日期:2018-12-01 00:00:00

  • A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

    abstract:INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clcc.2018.02.004

    authors: Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

    更新日期:2018-06-01 00:00:00

  • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

    abstract:BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2006.n.037

    authors: Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

    更新日期:2006-09-01 00:00:00

  • Patients with colorectal and renal cell carcinoma diagnoses appear to be at risk for additional malignancies.

    abstract:UNLABELLED:Patients with colorectal cancer (CRC) and renal cell carcinoma (RCC) may be at risk for additional primary malignancies. A review of 101 patients with these concurrent diagnoses was performed. Forty-two percent of patients had 1 or more additional malignancies; none appeared to be associated with Lynch syndr...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clcc.2012.07.004

    authors: Steinhagen E,Moore HG,Lee-Kong SA,Shia J,Eaton A,Markowitz AJ,Russo P,Guillem JG

    更新日期:2013-03-01 00:00:00

  • Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.

    abstract::The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2008.n.010

    authors: Bhaskara A,Eng C

    更新日期:2008-01-01 00:00:00

  • Preclinical data targeting vascular endothelial growth factor in colorectal cancer.

    abstract::Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2004.s.009

    authors: Ellis LM

    更新日期:2004-10-01 00:00:00

  • Is levoleucovorin an alternative to racemic leucovorin? A literature review.

    abstract:PURPOSE:Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. DESIGN:This is an extensive literature review of levoleucovorin use in patients with gastrointestinal...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2009.n.034

    authors: Kovoor PA,Karim SM,Marshall JL

    更新日期:2009-10-01 00:00:00

  • An adverse interaction between warfarin and fluoropyrimidines revisited.

    abstract::Regimens based on flouropyrimidines (eg, 5-fluorouracil [5-FU] and capecitabine) are the mainstay of chemotherapy for several malignancies, including colon, pancreatic, upper gastrointestinal, and breast cancers. Warfarin is one of the most commonly used oral anticoagulants. Patients receiving concomitant capecitabine...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2005.n.028

    authors: Saif MW

    更新日期:2005-09-01 00:00:00

  • Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

    abstract:BACKGROUND:Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin. A combination regimen using all 4 agents could potentially increase response rates in CRC. PATIENTS AND METHODS:A multicenter phase II trial of oxaliplatin ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CCC.2007.n.017

    authors: McWilliams RR,Goetz MP,Morlan BW,Salim M,Rowland KM,Krook JE,Ames MM,Erlichman C

    更新日期:2007-05-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract::Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.015

    authors: Moosmann N,Heinemann V

    更新日期:2008-03-01 00:00:00

  • Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.

    abstract::Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States. Despite excellent prognosis for early stage disease, 5-year survival rates in metastatic disease remain low. A small subset of CRC is defined by a deficiency in mismatch repair (dMMR) resulting in high levels of micro...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2020.02.002

    authors: Thomas J,Leal A,Overman MJ

    更新日期:2020-06-01 00:00:00

  • Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

    abstract::Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2006.s.005

    authors: von Mehren M

    更新日期:2006-11-01 00:00:00

  • Multidisciplinary perspective on the management of appendiceal adenocarcinoma: case review of 10 patients from a university hospital and current considerations.

    abstract:BACKGROUND:Adenocarcinoma of the vermiform appendix is rare. It constitutes less than 0.5% of all gastrointestinal malignancies. Pathologically, appendiceal neoplasms are categorized into various subtypes depending on cell lineage. PATIENTS AND METHODS:We considered a case series of appendiceal invasive adenocarcinoma...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2014.11.003

    authors: Bunni J,Arnold D,Shelley-Fraser G,Shabbir J

    更新日期:2015-03-01 00:00:00

  • Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.

    abstract:BACKGROUND:Treatment sequencing for patients with refractory metastatic colorectal cancer (mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib have demonstrated clinical benefits in randomized phase III trials compared with placebo. Ho...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.05.012

    authors: Unseld M,Drimmel M,Siebenhüner A,Gleiss A,Bianconi D,Kieler M,Scheithauer W,Winder T,Prager GW

    更新日期:2018-12-01 00:00:00

  • Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.

    abstract:INTRODUCTION:Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. METHODS:C...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clcc.2017.03.003

    authors: Lim A,Le Sourd S,Senellart H,Luet D,Douane F,Perret C,Bouvier A,Métairie S,Cauchin E,Rougier P,Matysiak-Budnik T,Touchefeu Y

    更新日期:2017-12-01 00:00:00

  • Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.

    abstract:BACKGROUND:New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic bi...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.02.008

    authors: Semaan A,Uhl B,Branchi V,Lingohr P,Bootz F,Kristiansen G,Kalff JC,Matthaei H,Pantelis D,Dietrich D

    更新日期:2018-06-01 00:00:00

  • Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders.

    abstract:BACKGROUND:The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma. PATIENTS AND METHODS:Between April 1988 and December 1996, 36 (cT2, n=9; cT3, n=27) patients ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2006.n.012

    authors: Rengan R,Paty PB,Wong WD,Guillem JG,Weiser M,Temple L,Saltz L,Minsky BD

    更新日期:2006-03-01 00:00:00

  • Adjuvant radiation therapy of patients with rectal cancer.

    abstract::The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2003.n.002

    authors: Bechtel J,Tepper J

    更新日期:2003-02-01 00:00:00

  • Laparoscopic radical correction combined with extensive lymphadenectomy and pelvic autonomic nerve preservation for mid-to-low rectal cancer.

    abstract:OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2011.03.025

    authors: Liu T,Zhang C,Yu P,Chen J,Zeng D,Gan L,Lv W,Liu L,Yan X

    更新日期:2011-09-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract:BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.06.004

    authors: Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期:2020-12-01 00:00:00

  • Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.

    abstract::The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be bet...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.039

    authors: Chibaudel B,Tournigand C,André T,Larsen AK,de Gramont A

    更新日期:2010-12-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract::The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2015.05.006

    authors: Lee MS,Kopetz S

    更新日期:2015-12-01 00:00:00

  • Rising Proportion of Young Individuals With Rectal and Colon Cancer.

    abstract:BACKGROUND:Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.10.002

    authors: Kasi PM,Shahjehan F,Cochuyt JJ,Li Z,Colibaseanu DT,Merchea A

    更新日期:2019-03-01 00:00:00

  • Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.

    abstract::Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2009.n.025

    authors: Bhattacharya A,Tóth K,Sen A,Seshadri M,Cao S,Durrani FA,Faber E,Repasky EA,Rustum YM

    更新日期:2009-07-01 00:00:00

  • Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.

    abstract:BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS:All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Nor...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.10.001

    authors: Guren MG,Aagnes B,Nygård M,Dahl O,Møller B

    更新日期:2019-03-01 00:00:00

  • Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

    abstract:BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.06.009

    authors: Tosi F,Sartore-Bianchi A,Lonardi S,Amatu A,Leone F,Ghezzi S,Martino C,Bencardino K,Bonazzina E,Bergamo F,Fenocchio E,Martinelli E,Troiani T,Siravegna G,Mauri G,Torri V,Marrapese G,Valtorta E,Cassingena A,Cappello G

    更新日期:2020-12-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract:BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.05.011

    authors: Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期:2020-09-01 00:00:00

  • Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS:Using a populatio...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.10.011

    authors: Loree JM,Tan SK,Lafond LM,Speers CH,Kennecke HF,Cheung WY

    更新日期:2018-03-01 00:00:00

  • Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy.

    abstract:INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS:T...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2016.08.003

    authors: Kinj R,Bondiau PY,François E,Gérard JP,Naghavi AO,Leysalle A,Chamorey E,Evesque L,Padovani B,Ianessi A,Benezery K,Doyen J

    更新日期:2017-09-01 00:00:00

  • Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.

    abstract::Combination protocols of 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan or oxaliplatin have demonstrated high activity in metastatic colorectal cancer. Capecitabine, an oral 5-FU prodrug, may replace infusional 5-FU/LV in combination protocols with irinotecan or oxaliplatin. We therefore initiated a phase II stud...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.3816/ccc.2004.n.009

    authors: Jordan K,Kellner O,Kegel T,Schmoll HJ,Grothey A

    更新日期:2004-05-01 00:00:00